HUAPONT LIFE SCIENCES(002004)

Search documents
华邦健康(002004)8月15日主力资金净流入1686.81万元
Sou Hu Cai Jing· 2025-08-15 09:03
通过天眼查大数据分析,华邦生命健康股份有限公司共对外投资了34家企业,参与招投标项目346次, 知识产权方面有商标信息109条,专利信息2条,此外企业还拥有行政许可10个。 来源:金融界 华邦健康最新一期业绩显示,截至2025一季报,公司营业总收入28.21亿元、同比减少3.24%,归属净利 润1.84亿元,同比增长18.50%,扣非净利润1.70亿元,同比增长14.34%,流动比率1.135、速动比率 0.915、资产负债率47.30%。 天眼查商业履历信息显示,华邦生命健康股份有限公司,成立于1992年,位于重庆市,是一家以从事医 药制造业为主的企业。企业注册资本197991.9191万人民币,实缴资本146083.29万人民币。公司法定代 表人为张松山。 金融界消息 截至2025年8月15日收盘,华邦健康(002004)报收于4.55元,上涨2.71%,换手率1.5%, 成交量28.18万手,成交金额1.27亿元。 资金流向方面,今日主力资金净流入1686.81万元,占比成交额13.26%。其中,超大单净流入1000.46万 元、占成交额7.87%,大单净流入686.36万元、占成交额5.4%,中单净流 ...
品牌价值节节高!华邦健康蝉联中国医药工业百强企业
Quan Jing Wang· 2025-08-13 05:51
Core Insights - The event highlighted the "2024 Annual Top 100 Enterprises in China's Pharmaceutical Industry," where Huabang Health (002004) was recognized as a leading pharmaceutical company again [1] - The ranking reflects the company's strong innovation drive and professional promotion capabilities within the pharmaceutical industry [1] Company Performance - Huabang Health has consistently focused on the health industry, enhancing its R&D investment, product quality control, and market channel expansion [1] - The company has improved its ranking since first being listed in 2020, showcasing its robust overall strength and industry leadership [1] Financial and Operational Highlights - In 2024, Huabang Health's medical business revenue showed steady growth, with bed utilization rates also improving [1] - The company placed significant emphasis on pharmaceutical R&D, achieving several milestones: four formulation products received market approval, one formulation product passed consistency evaluation, six raw material drug varieties and pharmaceutical excipients obtained A certification, and five raw material drug varieties received international certification [1] Product Development - Huabang Health is actively expanding into the dermatological product sector, launching two new functional skincare products to enhance its skin health product matrix [1] - The company aims to develop a comprehensive industry chain that integrates raw materials, formulations, functional skincare products, skin health management, and medical services [1]
华邦健康:合法合规收购百盛药业资产组
Zheng Quan Ri Bao Zhi Sheng· 2025-08-05 12:41
证券日报网讯 华邦健康8月5日在互动平台回答投资者提问时表示,公司严格遵守相关法律法规及监管 要求,合法合规收购百盛药业资产组,不存在利益输送行为。近年来,百盛药业资产组受药品集采等行 业政策影响,导致经营业绩出现大幅下滑,整体业务规模萎缩,故公司对其商誉计提减值。 (编辑 王雪儿) ...
华邦健康股价持平 复方樟脑乳膏具驱蚊防护功能
Jin Rong Jie· 2025-08-04 19:20
Core Viewpoint - Huabang Health's stock price remained stable at 4.41 yuan on August 4, with a trading volume of 232,683 hands and a transaction amount of 102 million yuan, indicating steady market interest in the company [1] Company Overview - The company operates in various sectors including pharmaceuticals, agricultural chemicals, and new materials [1] - In the pharmaceutical segment, Huabang Health offers a range of products in dermatology and tuberculosis, including the compound camphor ointment which provides mosquito repellent and itch relief [1] - The company also produces antihistamine medications such as levocetirizine hydrochloride tablets, which help alleviate skin itching [1] Recent Developments - On August 3, the company confirmed on its investor interaction platform that medication for chikungunya patients should be determined by professional medical personnel, and reiterated the mosquito repellent efficacy of the compound camphor ointment [1] - On August 4, the net inflow of main funds was 5.38 million yuan, with a cumulative net inflow of 21.42 million yuan over the past five days, reflecting positive investor sentiment [1]
华邦健康:公司生产的华邦复方樟脑乳膏具有驱蚊防护、叮咬止痒的作用
Mei Ri Jing Ji Xin Wen· 2025-08-04 03:49
(文章来源:每日经济新闻) 每经AI快讯,有投资者在投资者互动平台提问:公司皮肤类产品对基孔肯雅热能改善吗,防治蚊虫叮 咬有用吗? 华邦健康(002004.SZ)8月3日在投资者互动平台表示,公司生产的盐酸左西替利嗪片/口服液、苯磺贝 他斯汀片、阿伐斯汀胶囊等抗组胺药品对缓解皮肤瘙痒有一定帮助,但基孔肯雅热患者的具体用药需由 专业医疗人员结合患者临床症状确定。同时,公司生产的华邦复方樟脑乳膏具有驱蚊防护、叮咬止痒的 作用。 ...
华邦健康:基孔肯雅热患者的具体用药需由专业医疗人员结合患者临床症状确定
Zheng Quan Shi Bao Wang· 2025-08-03 01:15
Core Viewpoint - Huabang Health (002004) has indicated that its antihistamine products, including Levocetirizine Hydrochloride tablets/oral solution, Benzonatate tablets, and Bevacizumab capsules, can help alleviate skin itching, but specific medication for Chikungunya patients should be determined by healthcare professionals based on clinical symptoms [1] Group 1 - The company produces Levocetirizine Hydrochloride tablets/oral solution, Benzonatate tablets, and Bevacizumab capsules, which are effective in relieving skin itching [1] - The use of these medications for Chikungunya patients requires professional medical assessment [1] - Huabang's compound camphor cream is noted for its mosquito repellent properties and effectiveness in relieving itching from bites [1]
7月28日晚间重要公告一览
Xi Niu Cai Jing· 2025-07-28 10:17
Group 1 - Changhua Group received a product purchase contract for carbon-ceramic brake discs, with a total sales amount expected to exceed 100 million yuan over a 5-year lifecycle, starting mass production in Q2 2026 [1] - Zhongke Environmental reported a net profit of 196 million yuan for the first half of 2025, a year-on-year increase of 19.83%, with revenue of 848 million yuan, up 4.48% [1] - WuXi AppTec's net profit for the first half of 2025 grew by 101.92% to 8.561 billion yuan, with revenue of 20.799 billion yuan, a 20.64% increase [1][2] - Sujiao Technology's net profit decreased by 39.54% to 95.39 million yuan, with revenue down 13.75% to 1.776 billion yuan [1] - Jucheng Co. reported a net profit of 205 million yuan, a significant increase of 43.5%, with revenue of 575 million yuan, up 11.69% [1] Group 2 - Sanxiang New Materials plans to invest up to 300 million yuan in a zirconium-hafnium separation project, with a production capacity of 20,000 tons [1] - Koweil received government subsidies totaling 4.9752 million yuan, accounting for 10.14% of its audited net profit [1] - Xinhua Medical obtained two Class II medical device registration certificates for digital X-ray machines [1] - Huanxu Electronics reported a net profit of 638 million yuan, down 18.66%, with total revenue of 27.214 billion yuan, a slight decrease of 0.63% [1] - Zhenhua Co.'s general manager was fined 100,000 yuan for violations related to stock trading by his child [1] Group 3 - Huafeng Aluminum signed a raw material purchase contract worth over 7.2 billion yuan for a five-year period, committing to purchase at least 360,000 tons of raw materials [1] - Hongxin Technology received a project designation letter and procurement contract from a major domestic automotive brand [1] - Meihe Co. obtained a patent for a device used in supporting automatic flipping on conveyor lines in the automotive manufacturing sector [1] - Xin Hongye's subsidiary won a bid for an electrical penetration project worth 40.8831 million yuan [1] - Fuan Pharmaceutical's subsidiary received a drug registration certificate for an injection used in liver disease treatment [1] Group 4 - Tianzhong Precision's subsidiary's bankruptcy liquidation application was accepted by the court due to insufficient assets to cover debts [1] - Zhonghong Medical's subsidiary received medical device registration for infusion pumps and information collection systems [1] - Keda Li's subsidiary completed a capital increase, raising its registered capital from 200 million yuan to 400 million yuan [1] - Xingye Technology applied for a credit limit of 372 million yuan from Guangfa Bank [1] - Hengrui Medicine signed a collaboration agreement with GSK, involving a potential total payment of approximately 12 billion USD based on project milestones [1]
华邦健康: 关于公司董事减持股份预披露公告
Zheng Quan Zhi Xing· 2025-07-27 16:14
Group 1 - The core point of the announcement is that Wang Rong, the vice chairman of Huabang Health, plans to reduce his shareholding by selling up to 2,700,000 shares, which represents 0.1369% of the company's total share capital, within a three-month period from August 19, 2025, to November 18, 2025 [1][2] - As of the announcement date, Wang Rong holds 10,800,000 shares, accounting for 0.5474% of the company's total share capital [1] - The reduction will be conducted through centralized bidding and will not exceed 25% of his total shareholding [1] Group 2 - Wang Rong will comply with relevant regulations, including the Securities Law and the Shenzhen Stock Exchange's self-regulatory guidelines, during the share reduction process [2] - The implementation of the share reduction plan is subject to market conditions and the company's stock price, indicating potential uncertainties regarding the timing and pricing of the sales [2] - The share reduction will not lead to a change in the control of the listed company, nor will it significantly impact the company's governance structure, equity structure, or ongoing operations [2]
华邦健康(002004) - 关于公司董事减持股份预披露公告
2025-07-27 07:45
华邦生命健康股份有限公司 关于公司董事减持股份预披露公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假 记载、误导性陈述或重大遗漏。 证券代码:002004 证券简称:华邦健康 公告编号:2025035 1、本次拟减持的原因:股东个人资金使用需求; 2、股份来源:公司吸收合并北京颖泰嘉和生物科技股份有限公司发行的股 份、公司股权激励授予的股份及通过二级市场增持的股份(含历次分配转增); 3、减持数量:拟减持公司股份数量不超过 2,700,000 股; 持有本公司股份 10,800,000 股、占本公司总股本(剔除公司回购专用证券 账户中股份数量)比例 0.5474%的副董事长王榕先生计划自本公告披露之日起 15 个交易日后的 3 个月内(2025 年 8 月 19 日至 2025 年 11 月 18 日)以集中竞价 方式减持不超过本公司股份 2,700,000 股,占本公司总股本(剔除公司回购专用 证券账户中股份数量)比例 0.1369%。 一、股东的基本情况 (一)股东名称:王榕。 (二)截至本公告披露日,王榕先生持有公司股份 10,800,000 股,占公司 总股本(剔除公司回购专用 ...
7月17日医疗器械上涨0.78%,板块个股安杰思、华兰股份涨幅居前
Sou Hu Cai Jing· 2025-07-17 12:10
Industry Overview - As of July 17, the medical device industry rose by 0.78%, with a net capital outflow of 178.58 million [1] - A total of 89 stocks in the sector increased, while 31 stocks decreased [1] Top Decliners - The top ten decliners in the sector included: - ST Kelly (-6.72%) - Haooubo (-4.36%) - Tailin Biology (-2.04%) - Mountain Outside Mountain (-1.71%) - Botuo Biology (-1.59%) - Yirui Technology (-1.35%) - DR Sanyou Medical (-1.31%) - Jihigh Development (-1.24%) - Anxu Biology (-1.21%) - Aidi Te (-0.89%) [1][1] Notable Gainers - Notable gainers included: - Anjisi: 7.36% increase with a net capital outflow of 12.83 million - Hualan Co.: 5.22% increase with a net capital outflow of 5.90 million - Xinmai Medical: 5.11% increase with a net capital inflow of 6.21 million - Nanwei Medical: 4.45% increase with a net capital inflow of 19.79 million [1][1][1] Market Sentiment - The overall market sentiment in the medical device sector showed a mixed performance with significant capital outflows from certain stocks while others attracted investment [1]